Anemias:
Indications for: OXBRYTA
Sickle cell disease.
Adult Dosage:
Swallow tabs whole. If difficulty swallowing, tabs for oral susp may be used; disperse tabs for oral susp in room temp clear liquid (eg, water or clear soda) before swallowing. ≥12yrs: 1500mg once daily. Severe hepatic impairment: 1000mg once daily. Avoid concomitant strong or moderate CYP3A4 inducers; if unavoidable, increase dose to 2000mg once daily (with moderate CYP3A4 inducers); 2500mg once daily (with strong CYP3A4 inducers).
Children Dosage:
<4yrs: not established. Use tabs or tabs for oral susp based on the ability to swallow and body weight. Disperse tabs for oral susp in room temp clear liquid (eg, water or clear soda) before swallowing. 4–<12yrs (10–<20kg): 600mg once daily; (20–<40kg): 900mg once daily; (≥40kg): 1500mg once daily. Severe hepatic impairment (10–<20kg): 300mg once daily; (20–<40kg): 600mg once daily; (≥40kg): 1000mg (two 500mg tabs) or 900mg (three 300mg tabs for oral susp) once daily. Avoid concomitant strong or moderate CYP3A4 inducers; if unavoidable with moderate CYP3A4 inducers (10–<20kg): 900mg once daily; (20–<40kg): 1200mg once daily; (≥40kg): 2000mg (four 500mg tabs) or 2100mg (seven 300mg tabs for oral susp) once daily; if unavoidable with strong CYP3A4 inducers (10–<20kg): 900mg once daily; (20–<40kg): 1500mg once daily; (≥40kg): 2500mg (five 500mg tabs) or 2400mg (eight 300mg tabs for oral susp) once daily.
OXBRYTA Warnings/Precautions:
Severe hepatic impairment: reduce dose. Pregnancy. Nursing mothers: not recommended (during and for ≥2 weeks after the last dose).
See Also:
OXBRYTA Classification:
Hemoglobin S polymerization inhibitor.
OXBRYTA Interactions:
May be antagonized by strong or moderate CYP3A4 inducers; if unavoidable, increase voxelotor dose. May be potentiated by strong CYP3A4 inhibitors. Avoid concomitant sensitive CYP3A4 substrates with a narrow therapeutic index; if unavoidable, consider dose reduction of the substrate. May interfere with measurement of Hb subtypes by high-performance liquid chromatography.
Adverse Reactions:
Headache, diarrhea, abdominal pain, nausea, rash, pyrexia, vomiting; hypersensitivity reactions (discontinue if occur).
Generic Drug Availability:
NO
How Supplied:
Tabs—90; Tabs for Oral Susp—60, 90
